Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

New chemotherapies in gastric adenocarcinoma

New chemotherapies in gastric adenocarcinoma Summary Chemotherapy is still the most important component of systemic therapy in gastric cancer. It is not replaced by targeted agents so far. Novel chemotherapies like 5‑fluorouracil (5FU) prodrugs are applied. Agents such as nanoliposomal irinotecan or nanoparticle albumin-bound paclitaxel are still under investigation. In patients overexpressing the epithelial growth factor receptor 2 (HER2), the addition of trastuzumab to classical chemotherapy improves overall survival (OS) substantially and in second line setting the monoclonal antibody ramucirumab shows single agent activity as well as activity in combination with paclitaxel. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

New chemotherapies in gastric adenocarcinoma

memo - Magazine of European Medical Oncology , Volume 10 (3): 4 – Sep 1, 2017

Loading next page...
 
/lp/springer-journals/new-chemotherapies-in-gastric-adenocarcinoma-M7stEb6kdT
Publisher
Springer Journals
Copyright
2017 Springer-Verlag GmbH Austria
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-017-0354-0
Publisher site
See Article on Publisher Site

Abstract

Summary Chemotherapy is still the most important component of systemic therapy in gastric cancer. It is not replaced by targeted agents so far. Novel chemotherapies like 5‑fluorouracil (5FU) prodrugs are applied. Agents such as nanoliposomal irinotecan or nanoparticle albumin-bound paclitaxel are still under investigation. In patients overexpressing the epithelial growth factor receptor 2 (HER2), the addition of trastuzumab to classical chemotherapy improves overall survival (OS) substantially and in second line setting the monoclonal antibody ramucirumab shows single agent activity as well as activity in combination with paclitaxel.

Journal

memo - Magazine of European Medical OncologySpringer Journals

Published: Sep 1, 2017

References